Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lucid Diagnostics (LUCD) Change in Accured Expenses (2021 - 2025)

Lucid Diagnostics (LUCD) has disclosed Change in Accured Expenses for 5 consecutive years, with -$146000.0 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Change in Accured Expenses rose 95.82% year-over-year to -$146000.0, compared with a TTM value of -$616000.0 through Sep 2025, up 70.79%, and an annual FY2024 reading of -$4.7 million, down 206.71% over the prior year.
  • Change in Accured Expenses was -$146000.0 for Q3 2025 at Lucid Diagnostics, down from $349000.0 in the prior quarter.
  • Across five years, Change in Accured Expenses topped out at $2.9 million in Q4 2021 and bottomed at -$3.5 million in Q3 2024.
  • Average Change in Accured Expenses over 5 years is $133842.1, with a median of $162000.0 recorded in 2021.
  • The sharpest move saw Change in Accured Expenses surged 1577.16% in 2022, then plummeted 610.51% in 2024.
  • Year by year, Change in Accured Expenses stood at $2.9 million in 2021, then crashed by 186.13% to -$2.5 million in 2022, then soared by 199.44% to $2.5 million in 2023, then tumbled by 102.52% to -$63000.0 in 2024, then plummeted by 131.75% to -$146000.0 in 2025.
  • Business Quant data shows Change in Accured Expenses for LUCD at -$146000.0 in Q3 2025, $349000.0 in Q2 2025, and -$756000.0 in Q1 2025.